---

Management of Coats’ disease with RazumabTM (World’s first biosimilar ranibizumab) and laser photocoagulation: A case report

---

Case Report

Author Details : Bhagwati Prasad Sharma, Shashikant Sharma*

Volume : 7, Issue : 1, Year : 2021

Article Page : 246-249

https://doi.org/10.18231/j.ijceo.2021.050

Suggest article by email

Get Permission

---

Abstract

We report a case of a 19-year-old Indian male with stage 2 Coats’ disease who was managed with monthly intravitreal biosimilar ranibizumab injections (n=3) along with laser photocoagulation in the right eye. Post-treatment, significant reductions were seen in the exudation, angioma-like lesions, central macular thickness and edema in the retina. At the last follow-up at 9 months after intravitreal biosimilar ranibizumab initiation, distant vision improved from best corrected visual acuity (BCVA) of 5/60 at baseline to 6/18, and near vision from ‘not able to read’ to N/12 in the right eye.

Keywords: Biosimilar, Coats’ disease, Laser photocoagulation, Ranibizumab.

How to cite : Sharma B P , Sharma S , Management of Coats’ disease with RazumabTM (World’s first biosimilar ranibizumab) and laser photocoagulation: A case report. Indian J Clin Exp Ophthalmol 2021;7(Special Issue):246-249

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.